DelfaGLP-1 Atlas

← Trials/Trial dossier/NCT01473147

AGAC2

CompletedPhase NA

Additional GLP-1 Analogue on CSII Treatment for Poorly Controlled Type 2 Diabetic Patients

Asset

Exenatide

Subcutaneous · GLP-1 agonist

Listed sites

1

Recruiting sites

—

Enrollment

51

actual

Study population

Type 2 diabetes

Key I/E criterion

•HbA1c 8-12%

Primary endpoint

•Mean amplitude of glycaemic excursions (MAGE)

Footprint

Where this trial recruits

Site locations as reported to ClinicalTrials.gov. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT01473147
Org study IDCMRPG3A0911

Timeline

Milestones

Study first posted2011-11-17estimated
Last update posted2013-07-30estimated
Study start2011-10 (month precision)
Primary completion2013-06actual (month precision)
Study completion2013-06actual (month precision)

Assets

Investigational agents

Exenatide

Study populations

Who this study enrolls

Type 2 diabetes

Eligibility

Who can enroll

Minimum age20 Years
Maximum age80 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Age > 20 years old
•DM diagnosed > 2 years
•HbA1c level of 8% to 12%
•Receiving insulin premixed insulin twice daily and total insulin daily dose > 0.6 u/kg/day

Exclusion criteria

•Severe comorbidity, including CHF, CVA, liver cirrhosis, COPD, Cushing's syndrome etc.
•Psychologic problems, including anxiety
•Incorporation, including personal and familial factors

Endpoints (2)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Mean amplitude of glycaemic excursions (MAGE)

Time frame:During 6-day treatment course

descriptive, improvement

Secondary/protocol endpoint

homeostasis model assessment(HOMA)

Time frame:During 6-day treatment course

HOMA-IR (insulin sensitivity)

change from baseline, improvement

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 1, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.